Clinical trials: Systemic Scleroderma
Systemic Sclerosis (SSc), Magnetic Resonance Imaging (MRI)
7.0 Tesla Resonance Magnetic Imaging of the Hand in Systemic Sclerosis
Systemic sclerosis (SSc) is a rare systemic autoimmune disease with specific osteoarticular pattern of unknown mechanism. Ischemic phenomenon have been suggested to participate to the osteoarticular involvement in SSc.
- Trial name
- PREM'S (NCT04223817)
- Testing
- 7.0 T RMI
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Poitiers University Hospital
Systemic Sclerosis, Systemic Scleroderma
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
Eosinophils are involved in tissue remodeling and fibrosis in many inflammatory diseases. Systemic sclerosis (SSc) is an autoimmune disease with fibrotic skin and lung complications.
- Trial name
- EOFIB-SSC (NCT03816189)
- Testing
- Blood test, Skin biopsies
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06373081
- Testing
- Anti-CD19-CD3E-CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Changzheng Hospital
Systemic Sclerosis With Dysphagia
Clinical Usefulness and Influence on Esophageal Motility of Pyridostigmine for Dysphagia in Systemic Sclerosis
Systemic sclerosis is characterized by progressive fibrosis of different organ systems. With a longer duration, the risk of gastrointestinal involvement increases.
- Trial name
- NCT06915181
- Testing
- Pyridostigmine
- Sponsor
- Universitair Ziekenhuis Brussel
Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
The Small Intestine Bacterial Overgrowth Study Pilot
This is a pragmatic study in which will compare a detailed treat-to-target (T2T) treatment algorithm to standard care for SSc SIBO at multiple sites around the world.
- Trial name
- SIBO (NCT03588845)
- Testing
- Treatment Protocol, Standard of Care
- Where
- 2 sites in United States, Australia
- Volunteers
- 500 people
- Sponsor
- Canadian Scleroderma Research Group
Systemic Sclerosis
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in…
- Trial name
- NCT00704665
- Testing
- Relaxin
- Volunteers
- 231 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Systemic Sclerosis, Digital Ulcers
Digital Ulceration
The CAP study is a multicenter, observational, clinical study in patients with systemic sclerosis. The study aims at determining the usefulness of nailfold videocapillaroscopy and patient-specific disease-related factors in…
- Trial name
- CAP (NCT01377090)
- Where
- 50 sites in Austria, Belgium and 13 more
- Volunteers
- 630 people
- Sponsor
- Actelion
Systemic Sclerosis, Gougerot Sjogren Syndrome
Echo Systemic Sclerosis
Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs.
- Conditions
- Systemic Sclerosis, Gougerot Sjogren Syndrome, Sicca-Asthenia-Polyalgia Syndrome
- Trial name
- NCT03143413
- Testing
- Ultrasonography
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Interstitial Lung Disease, Systemic Sclerosis
The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis
Scarring of the lungs is common in patients with scleroderma and is one of the main causes of death. Patients with scleroderma very frequently have problems with their gullet (esophagus), the food pipe that leads into the…
- Conditions
- Interstitial Lung Disease, Systemic Sclerosis, Gastroesophageal Reflux
- Trial name
- NCT02136394
- Testing
- Gastro-esophageal reflux
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus, Systemic Scleroderma
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase.
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma, ANCA-associated Vasculitis, Antiphospholipid Syndrome
- Trial name
- AutoB-Tetramer (NCT07251179)
- Testing
- blood draw
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa…
- Trial name
- NCT02339961
- Testing
- Ultrasound radiation
- Sponsor
- Echosense Ltd.
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
Scleroderma, Systemic
A Comparison Between Two Educational Methods in the Rehabilitation of the Microstomia in Systemic Sclerosis
Background: A typical feature of SSc is the fibrotic involvement of the connectival tissue of the face, which causes microstomia.
- Trial name
- SScM398-1 (NCT03766243)
- Testing
- Brochure and DVD plus nursing training, Brochure and DVD only
- Volunteers
- 39 people
- Sponsor
- IRCSS Istituto Dermopatico dell'Immacolata, Fondazione Luigi Maria Monti
Scleroderma, Systemic
The Benefit of Bermekimab in Patients With Systemic Sclerosis
This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc.
- Trial name
- NCT04045743
- Testing
- MABp1 (Bermekimab)
- Where
- 2 sites in Greece
- Volunteers
- 20 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Diffuse Cutaneous Systemic Sclerosis
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period.
- Trial name
- NCT04138485
- Testing
- IgPro10
- Where
- 77 sites in United States, Argentina and 11 more
- Sponsor
- CSL Behring
Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences.
- Trial name
- FASST (NCT02503644)
- Testing
- IVA337
- Where
- 49 sites in Bulgaria, France and 8 more
- Volunteers
- 145 people
- Sponsor
- Inventiva Pharma
Scleroderma, Systemic Sclerosis
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma,also known as systemic sclerosis (SSc), is a multisystem disease affecting skin and other tissues including joints, muscles, lungs, the gastrointestinal tract and kidneys and tissue fibrosis is widespread.
- Conditions
- Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
- Trial name
- NCT01538719
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University
Pulmonary Hypertension
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a condition characterized by an increased pulmonary vascular resistance that can lead to right heart failure and death.
- Trial name
- NCT01729611
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- The Cleveland Clinic